Dosing and Pharmacokinetics of Verapamil and Diltiazem

Key Differences in Dosing Frequency and Pharmacokinetics

The American Heart Association recommends Diltiazem ER to be dosed once daily at 120-360 mg, while Verapamil IR requires three times daily dosing at 120-360 mg, and Verapamil SR requires 1-2 times daily dosing at 120-360 mg 1, 2
Both drugs are CYP3A4 major substrates and moderate inhibitors, creating similar drug interaction profiles, as stated by the American College of Cardiology 1, 2
The antianginal effects of both drugs are mediated by similar mechanisms: peripheral vasodilation and reduction in myocardial oxygen demand, according to the European Society of Cardiology 3

The American College of Cardiology recommends avoiding both drugs in patients with heart failure with reduced ejection fraction (HFrEF) or left ventricular systolic dysfunction, as well as in patients already on beta-blockers, due to the risk of severe bradycardia and high-degree AV block 1, 2, 3
The European Society of Cardiology advises against using these drugs in patients with significant sinus or AV node dysfunction, hypotension, or spontaneous paroxysmal AF, due to the potential to sustain the arrhythmia 3, 4

The American Heart Association suggests choosing Diltiazem ER when once-daily dosing is critical for medication adherence, or when the patient requires rate control for atrial fibrillation 1, 2, 3
The European Society of Cardiology recommends choosing Verapamil when the patient has hypertension with supraventricular tachycardias, hypertrophic cardiomyopathy, or when beta-blockers are contraindicated or produce intolerable side effects 4

The American College of Cardiology recommends initiating with low doses regardless of which agent is chosen, and monitoring heart rate and PR interval due to the negative chronotropic effects of both drugs 4, 5
The European Society of Cardiology advises reassessing patients in 1-2 weeks and adjusting dosing based on clinical response, rather than assuming dose equivalence 4